Top Story Today
Every Untreated Mouse Died. Every Treated Mouse Healed. The Gel That Could End Diabetic Amputations.
In a study published in Nature Communications Materials, every single untreated diabetic mouse died from chronic wound failure. Every single mouse that received a new oxygen-pumping gel survived and fully healed within 23 days. The UC Riverside team built a battery-powered gel that continuously delivers oxygen deep into tissue, tackling the root cause of non-healing wounds — a condition called hypoxia, where tissue is basically suffocating from oxygen starvation. The gel also uses choline to cool inflammation and neutralize the destructive molecules that accumulate in chronic wounds. Diabetic foot ulcers remain the leading cause of non-traumatic amputation worldwide, affecting millions of patients with few good options.
Why it matters: If this works in humans, it could transform care for millions of diabetic patients facing amputation. But the real sleeper application might be even bigger — a reliable method for delivering oxygen into thick tissue could become critical infrastructure for the entire lab-grown organ field, where passive diffusion alone can't keep engineered tissue alive.
Read more →Investment & Strategy
A $9 Billion Biotech Sitting on $16 Billion Worth of Pipeline — With Patent Cliffs That Don't Arrive Until the 2040s
Axsome Therapeutics has a late-stage CNS pipeline with $16 billion in peak sales potential, nearly double its $9.3 billion market cap. Patent protection runs into the 2040s, so there are no looming exclusivity cliffs to worry about. Their antidepressant Auvelity is expanding into Alzheimer's agitation — a 5-million-patient U.S. market with almost no competition — while AXS-12 for narcolepsy targets a regulatory filing by Q4 2026.
Read more →Global Pharma & Supply Chain
India's Generic Drug Exports Just Crossed $30 Billion, and the Industry Wants to Go Faster
India's pharma exports hit $30.47 billion in 2024-25, up 9.4% year-over-year, tightening the country's already firm grip on global generic supply. Industry leaders are now pushing for double-digit growth by targeting regulated U.S. and EU markets. For Western biopharma, that translates to more pricing pressure on generics and a deeper bench of CDMO manufacturing partners to choose from.
Read more →